IRVINE, California, June 20, 2016 /PRNewswire/ --

Post-market Clinical Study Evaluates Axonics Miniaturized, Rechargeable System for Overactive Bladder Patients

Axonics Modulation Technologies, Inc., the developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that its first patients were successfully implanted at both the National Hospital for Neurology and Neurosurgery in London and Maastricht University Medical Centre in the Netherlands.

The patients were treated as part of a 65-patient post-market clinical follow-up study (RELAX-OAB) designed to confirm the performance of the Axonics SNM System as an aid in the treatment of the symptoms of Overactive Bladder (OAB).

The Axonics SNM System received CE Mark in early June 2016 and patients are currently being enrolled in the study at leading medical centers in England, Belgium, the Netherlands and France. The first implant procedure was performed in London by Sohier Elneil, M.D., Ph.D. and three additional implants were performed by Professor Philip van Kerrebroeck, M.D., Ph.D. in Maastricht.

"This miniaturized rechargeable SNM System represents a major step forward for patients seeking a long-term solution to relieve overactive bladder symptoms and improve their quality of life. The implant is expected to be functional for at least 15 years in the body, which is more than three times longer than current non-rechargeable systems," said Professor van Kerrebroeck.

OAB affects an estimated 85 million adults in the US and Europe. Sacral Neuromodulation therapy is an effective and durable treatment that has been widely used and reimbursed in Europe and the US for the past two decades. Over 200,000 patients have benefited from the therapy to date. Sacral Neuromodulation is the only OAB treatment with proven clinical superiority to standard drug therapy.

"The implantation procedure of the Axonics System was quick and easy and consistent with our current Sacral Neuromodulation implant practices," said Dr. Elneil. "Our patients are excited to have the option of an implant with such a small size and long life. We will closely follow the patients and are confident they will experience significant relief of their overactive bladder symptoms."

Earlier this month, Axonics announced that Neurourology and Urodynamics published the results of a peer-reviewed study titled, "Cost Profiles and Budget Impact of Rechargeable Versus Non-Rechargeable Sacral Neuromodulation Devices in the Treatment of Overactive Bladder Syndrome." The study findings determined that compared to non-rechargeable Sacral Neuromodulation systems for the treatment of OAB, a rechargeable system with a long-lived battery could save healthcare systems billions over the next 15 years. Physicians and researchers who collaborated on the study included Karen L. Noblett, M.D., University of California, Riverside; Roger R. Dmochowski, M.D., Vanderbilt University; Sandip P. Vasavada, M.D., Cleveland Clinic, Abigail M. Garner, M.S.; Shan Liu, Ph.D. and Jan B. Pietzsch, Ph.D. of Wing Tech, Inc., Menlo Park, CA.

About the Axonics Sacral Neuromodulation System™ 

The Axonics SNM System is a rechargeable implantable neuromodulation system that modulates sacral nerve activity for the management of urinary and fecal dysfunction. The System includes, among other innovations, a miniaturized implantable pulse generator that is 60 percent smaller and is qualified to last at least 15 years in the body - more than three times longer than currently marketed non-rechargeable Sacral Neuromodulation technology. In addition, the Axonics SNM System features both a key-fob sized patient-friendly remote control and an intuitive clinician programmer that guides physician implanters throughout the procedure, from lead placement to programming.

About Axonics Modulation Technologies, Inc. 

Axonics, based in Irvine, CA, is a privately held venture backed company developing novel implantable neuromodulation technology directed toward a number of clinical indications. Investors include Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management and The Alfred E. Mann Foundation. For more information, visit the Company's website at

http://www.axonicsmodulation.com

# # #

Media Contact
Susan Heins
Pure Communications, Inc.
+1-864-346-8336
sjheins@purecommunicationsinc.com

Investor Contact
Matt Clawson
Pure Communications, Inc.
+1-949-370-8500
matt@purecommunicationsinc.com

SOURCE Axonics Modulation Technologies, Inc.